Palabras clave
Neoplasias del endometrio
Endometrio
Levonorgestrel
Cáncer de endometrio
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Realizar una revisión exhaustiva de la literatura sobre el cáncer de endometrio y su relación con el Dispositivo Intrauterino (DIU) liberador de Levonorgestrel, evaluando su potencial como factor protector en la prevención de esta neoplasia. Métodos: Se llevó a cabo una investigación exploratoria de carácter cuantitativo, tipo revisión de literatura en las bases de datos PubMed Medline, BVS, ScienceDirect (Elsevier) y Portal de Periódicos CAPES. Se utilizaron los términos: "LNG-IUD", "Endometrial cancer", "Cancer risk", "Levonorgestrel", "Dispositivos Intrauterinos", "Neoplasias do Endométrio", "Endométrio" y "Levonogestrel". Se seleccionaron artículos relevantes disponibles para acceso público. Resultados: En PubMed, diez artículos indicaron que el DIU liberador de levonorgestrel provoca cambios en el endometrio, reduciendo significativamente el sangrado y la proliferación celular. En el Portal de Periódicos CAPES, diez artículos mostraron que el DIU está asociado con una menor incidencia de cáncer de endometrio, especialmente en mujeres obesas. En la BVS, cuatro artículos confirmaron la eficacia del DIU hormonal en el tratamiento de la hiperplasia endometrial, siendo una alternativa eficaz a los progestágenos orales. Conclusión: El Dispositivo Intrauterino liberador de Levonorgestrel (DIU) puede jugar un papel importante en la prevención y tratamiento del cáncer de endometrio, reduciendo el riesgo de cáncer y promoviendo la regresión de la hiperplasia endometrial.
Referencias
BAKER WD, et al. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecologic Oncology, 2017; 146(1): 34-38.
BERNARD L, et al. The levonorgestrel intrauterine system (LNG-IUS) for prevention of endometrial cancer in women with obesity is cost effective. FREEDOM, 2021; 162(2): 300-301.
BRASIL. Hiperplasia endometrial e câncer do endométrio. São Paulo: Federação Brasileira das Associações de Ginecologia e Obstetrícia (Febrasgo); 2018. Disponível em: https ://docs.bvsalud.org/biblioref/2019/12/1046498/femina-2019-472-105-109.pdf. Acesso em: 5 abr. 2024.
CORTESSIS VK, et al. Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. Journal of Obstetrics & Gynecology, 2017; 130(6): 1226-1236.
CROSBIE EJ, et al. Endometrial cancer. Lancet. 2022; 399(10333): 1412-1428.
DERBYSHIRE AE, et al. PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study. Cancer Prevention Research. Filadélfia, 2021; 14(2): 263-274.
DHAR KK, et al. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecologic Oncology. 2005; 97(3): 924-927.
EDELMAN A e KANESHIRO B. Contraception: Counseling for females with obesity. UpToDate, 2024.
ELASSALl GM, et al. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis. Journal of Gynecology Obstetrics and Human Reproduction, 2022; 51(8): 102432.
FELIX AF, et al. Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer, 2015; 136(5): 989-1243.
GALLOS ID, et al. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Human Reproduction, 2013; 28(11): 2966-2971.
GOLDSTUCK ND. The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives. The European Journal of Contraception & Reproductive Health Care, 2023; 28(3): 177–183.
GOMPEL A. Progesterone and endometrial cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 2020; 69: 95-107.
GUTTINGER A e CRITCHLEY HOD. Endometrial effects of intrauterine levonorgestrel. Contraception, 2007; 75(6): 93-98.
HIRATA T, et al. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer. The Journal of Obstetrics and Gynaecology Research, 2022; 48(12): 3219-3225.
JAREID M, et al. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecologic Oncology, 2018; 149(1): 127-132.
MACKINTOSH ML e CROSBIE EJ. Prevention Strategies in Endometrial Carcinoma. Current Oncology Reports, 2018; 20(11): 101.
MADDEN T. Intrauterine contraception: Candidates and device selection. UpToDate, 2024.
MARKOWSKA A et al. Endometrial Cancer Management in Young Women. Cancers, 2022; 14(8): 1922.
MEER ACL e HANNA LS. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clinical Obesity, 2017; 7(1): 54-57.
MITTERMEIER T e FARRANT C, et al. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database of Systematic Reviews, 2020; 6(9).
MORELLI M, et al. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecological Endocrinology, 2013; 29(2): 156-159.
MUECK AO e SEEGER H, et al. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocrine-Related Cancer, 2010; 17(4): 263-271.
NOVIKOVA OV, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. Gynecologic Oncology. Elsevier, 2021; 161(1): 152-159.
SILVA FC, et al. Avaliação da influência do uso de métodos contraceptivos sobre os resultados dos esfregaços de Papanicolaou. Acta Scientiarum. Health Sciences, 2006; 28(1): 65-70.
SOINI T, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Journal of Obstetrics & Gynecology, 2014; 124(2-1): 292-299.
TANIGUCHI I, et al. Weight-Loss Interventions and Levonorgestrel Intrauterine System Implantation for Early-Stage Endometrial Cancer and Atypical Endometrial Hyperplasia to Reduce Perioperative Risk of Severely Obese Patients. Gynecology and Minimally Invasive Therapy, 2023; 12(3): 175-178.
WAN YL e HOLLAND C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric, 2011; 14(6): 622-632.
WASHINGTON CR, et al. Knowledge of endometrial cancer risk factors in a general gynecologic population. Gynecologic Oncology, 2020; 158(1): 137-142.